Bavarian Nordic wins decade-long contract with Canada
The Danish drugmaker has expanded its monkeypox/smallpox vaccine contract with the Canadian government to last ten years, increasing its total value of up to USD 470m.
by christian bundgaard, translated by daniel pedersen
Bavarian Nordic’s monkeypox/smallpox vaccine, regionally branded as either Imvanex, Jynneos, or Imvamune, has proven a very lucrative business for the Danish drugmaker this year.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Monkeypox on decline in US
For subscribers
